Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634595 | 1.00 | GSK3B (0.48) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL26634300 | 1.00 | GSK3B (0.48) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL26634290 | 1.00 | GSK3B (0.48) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL26634376 | 0.89 | GSK3B (0.58) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL26634386 | 0.89 | GSK3B (0.58) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL26634381 | 0.89 | GSK3B (0.58) | GSK3BCYP1A2SMN1; SMN2ROCK2ALDH1A1 | |
| SCHEMBL10326493 | 0.79 | CREBBP (0.51) | CYP1A2SMN1; SMN2ALDH1A1POLBCYP3A4 | |
| SCHEMBL30634601 | 0.79 | CREBBP (0.51) | CYP1A2SMN1; SMN2ALDH1A1POLBCYP3A4 | |
| SCHEMBL10326919 | 0.79 | CREBBP (0.51) | CYP1A2SMN1; SMN2ALDH1A1POLBCYP3A4 | |
| SCHEMBL17676990 | 0.79 | CREBBP (0.51) | CYP1A2SMN1; SMN2ALDH1A1POLBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4518968-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | Cytokinetics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023215367-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296916-A1 | BICYCLIC PIPERAZINONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNI3, TNNC1 | GSK3B 2604/4885CYP1A2 2484/4885SMN1; SMN2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.